Repare Therapeutics to Regain Global Rights to Camonsertib Following Collaboration Termination with Roche” Repare Therapeutics Inc. (Nasdaq: RPTX), a prominent clinical-stage precision oncology company, has announced its intention to reclaim global development and commercialization rights to camonsertib (RP-3500), a potential…
Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and its parent company, Otsuka Pharmaceutical Co., Ltd. (Otsuka), have disclosed the topline findings from the phase 3 clinical trial of AVP-786 aimed at treating agitation associated with dementia due to Alzheimer’s disease…
Medpace Holdings, Inc. (Nasdaq: MEDP) has released its financial results for the fourth quarter and full year ending December 31, 2023. Fourth Quarter 2023 Financial Highlights: Full Year 2023 Financial Highlights: Balance Sheet and Liquidity: Source link
Baxter International Inc. (NYSE:BAX), a leading global medtech company, has announced its financial results for the fourth quarter and full year ending Dec. 31, 2023, alongside providing financial guidance for full-year and first-quarter 2024. José (Joe) E. Almeida, Chair, President,…
Regardless of one’s identity, hearing the diagnosis “you have cancer” initiates a whirlwind of emotions, ranging from shock and disbelief to acceptance and determination. As clinicians, the moment we convey these words, patients yearn for comprehensive information to swiftly develop…
Amidst the growing landscape of cell and gene therapy (CGT) products in clinical development, Cencora’s FormularyDecisions has unveiled a new resource tailored to offer healthcare payers centralized access to information on approved therapies and those in the pipeline. FormularyDecisions, a…
HCA Healthcare, Inc. (NYSE:HCA), a prominent healthcare provider in the United States, has announced that its HCA Healthcare Hope Fund, a 501(c)3 public charity offering emergency aid to colleagues facing significant hardships such as illness, injury, natural disasters, or other…
For the fifth year running, MEDITECH’s Expanse platform maintains its dominant position at the forefront of the KLAS leaderboard. In the 2024 Best in KLAS: Software & Services report, Expanse has secured the top rank for Acute Care EHR: Small…
The ResearchAndMarkets.com platform now includes the “Fetal Doppler Market – Global Outlook & Forecast 2023-2028” report in its offerings. The global fetal Doppler market is poised for significant advancement driven by heightened at-home usage, integration with mobile apps, and a…
Relatient, a premier patient scheduling platform, has clinched the top spot as the Best in KLAS patient self-scheduling solution according to KLAS Research. This prestigious recognition stems from extensive feedback gathered from thousands of providers over the course of 2023.…
The second sentence of the first paragraph of the release should read: “Six studies, presented at the International Stroke Conference (ISC) 2024, have shown positive outcomes with real-world impact of Viz.ai in clinical practice across various neurology pathologies including acute…
Following our previous update on January 5, 2024, we are delighted to share the latest advancements with you. A Phase I dose-ranging clinical trial investigating DFP-14927 in patients with solid tumors has been successfully conducted at MD Anderson Cancer Center…